8-K: ARCHIMED Completes ZimVie Acquisition for $19/Share

Sentiment:

Merger Completion Announcement 20 October 2025 1:09 PM

ARCHIMED has completed its acquisition of ZimVie Inc., taking the global dental implant leader private at $19.00 per share.

Capital raiseThe merger consideration was funded through equity contributions received by Zamboni Parent Inc.Proceeds from a new First Lien Credit Agreement with Golub Capital LLC were also used for funding the acquisition.

Summary

ZimVie Inc. was acquired by Zamboni Parent Inc., a wholly owned subsidiary of ARCHIMED, on October 20, 2025.
Each outstanding share of ZimVie common stock converted into the right to receive $19.00 in cash, without interest.
Restricted stock units (RSUs) and deferred stock units (DSUs) vested in full and converted into cash based on the $19.00 per share merger consideration.
Stock options vested in full and converted into cash for the excess (if any) of $19.00 over their per share exercise price.
ZimVie's common stock ceased trading on NASDAQ and will be delisted, with the delisting effective on October 30, 2025.
The company intends to file Form 15 with the SEC to terminate registration and suspend reporting obligations under the Exchange Act.
The acquisition was funded through equity contributions from Zamboni Parent Inc. and proceeds from a new First Lien Credit Agreement with Golub Capital LLC.
The previous Credit Agreement, dated December 17, 2021, with JPMorgan Chase Bank, N.A., was repaid in full and terminated.

Sentiment

Score: 7

Explanation: The completion of the acquisition provides certainty and liquidity to former shareholders at a pre-agreed price. For the company, it marks a transition to private ownership with a specialized healthcare investor, which could be beneficial for long-term strategic growth without public market pressures. The sentiment is positive for the finalization of the deal, though it removes public investment opportunity.

Positives

Shareholders received a definitive cash payment of $19.00 per share, providing immediate liquidity and a clear return on investment.
Equity award holders (RSUs, DSUs, Options) received cash payouts, monetizing their holdings.
ZimVie gains a strategic partner in ARCHIMED, an investment firm exclusively focused on healthcare, which could accelerate growth as a private entity by leveraging specialized industry expertise and capital.

Negatives

ZimVie common stock is no longer publicly traded, removing future public market upside and liquidity for former shareholders.
The company's reporting obligations under the Exchange Act will be suspended, reducing transparency for public investors and analysts.

Future Outlook

ZimVie will operate as a privately held company under ARCHIMED's ownership, aiming to accelerate growth as a global leader in the dental implant market. The company intends to terminate its SEC registration and reporting obligations, transitioning fully out of the public market.

Management Comments

"We are excited to partner with ZimVie to accelerate its growth as a global leader in the dental implant market." (Andr-Michel Ballester, Managing Partner at ARCHIMED)
"ZimVie's proven innovation, trusted brand, and strong clinical heritage align perfectly with ARCHIMED's mission to support world-class healthcare companies." (Andr-Michel Ballester, Managing Partner at ARCHIMED)

Industry Context

This acquisition reflects a broader trend of private equity firms investing in specialized, high-growth healthcare sectors like dental implants. ARCHIMED's exclusive focus on healthcare suggests a strategic alignment to enhance ZimVie's market position and innovation capabilities, potentially allowing for more agile strategic decisions away from public market pressures.

Management Changes

Role	Previous Person	New Person	Effective Date	Reason
Director	Vafa Jamali		October 20, 2025	Resigned upon consummation of merger
Director	Sally Crawford		October 20, 2025	Resigned upon consummation of merger
Director	Vinit Asar		October 20, 2025	Resigned upon consummation of merger
Director	Dr. Richard E. Kuntz		October 20, 2025	Resigned upon consummation of merger
Director	Karen Matusinec		October 20, 2025	Resigned upon consummation of merger
Director		Andr-Michel Ballester	October 20, 2025	Appointed upon consummation of merger
Director		Bryan Alterman	October 20, 2025	Appointed upon consummation of merger
Officer	Vafa Jamali		October 20, 2025	Resigned upon consummation of merger
Officer	Richard Heppenstall		October 20, 2025	Resigned upon consummation of merger
Officer	Indraneel Kanaglekar		October 20, 2025	Resigned upon consummation of merger
Officer	Heather Kidwell		October 20, 2025	Resigned upon consummation of merger
Officer	Steve Rondeau		October 20, 2025	Resigned upon consummation of merger
Officer	Ruth Lopez		October 20, 2025	Resigned upon consummation of merger
Officer	Sandra Schneider		October 20, 2025	Resigned upon consummation of merger
Officer		Andr-Michel Ballester	October 20, 2025	Appointed upon consummation of merger
Officer		Bryan Alterman	October 20, 2025	Appointed upon consummation of merger

Corporate Governance

Change Type	Description	Effective Date	Impact Assessment
Certificate of Incorporation Amendment	The Certificate of Incorporation was amended and restated in its entirety, reducing authorized capital stock to 1,000 shares of common stock and detailing new provisions for dividends, liquidation, voting, director liability, and indemnification.	October 20, 2025	Reflects the company's transition to a privately held entity with a simplified capital structure and governance tailored for a wholly-owned subsidiary, removing provisions relevant to public shareholders.
Bylaws Amendment	The Bylaws were amended and restated in their entirety, aligning with the new corporate structure as a private entity and reflecting changes in board composition and operational procedures.	October 20, 2025	Streamlines internal governance for a private company, removing provisions relevant to public shareholders and board structures.

Stakeholder Impact

Shareholders: Received a cash payment of $19.00 per share, concluding their investment in the public entity.
Employees: Key management and board members have changed, with new leadership appointed by the acquiring entity. The broader impact on employees is not detailed but the company continues operations under new ownership.
Customers and Suppliers: Expected to continue business relationships, potentially benefiting from ARCHIMED's strategic investment and focus on the dental implant market.
Creditors: Previous debt facilities were repaid, and new debt financing was established to fund the acquisition.

Next Steps

ZimVie will operate as a wholly owned subsidiary of Zamboni Parent Inc. (ARCHIMED).
NASDAQ will delist ZimVie Common Stock, effective October 30, 2025.
ZimVie intends to file Form 15 with the SEC to terminate registration under Section 12(g) and suspend reporting obligations under Sections 13 and 15(d) of the Exchange Act.

Key Dates

Date	Description
2021-12-17	Date of previous Credit Agreement with JPMorgan Chase Bank, N.A.
2025-07-20	Date ZimVie Inc. entered into the Agreement and Plan of Merger with Zamboni Parent Inc. and Zamboni MergerCo Inc.
2025-10-13	ZimVie notified NASDAQ of the anticipated closing of the Merger.
2025-10-20	Merger consummated; ZimVie became a wholly owned subsidiary of Parent; new First Lien Credit Agreement entered; previous Credit Agreement terminated; NASDAQ filed Form 25 for delisting; press release issued.
2025-10-30	Effective date of delisting of Company Common Stock from NASDAQ.

Recommendation

sell

The company's common stock has been acquired, and shareholders received a cash payment of $19.00 per share. The stock is no longer trading on NASDAQ, and the company will cease to be publicly reported. Therefore, any remaining public shares should be considered sold, and there is no further investment opportunity in the public market for this entity.

Keywords

ZimVie, ARCHIMED, Acquisition, Merger, Dental Implants, Life Sciences, Healthcare Investment, Delisting, Private Equity, ZIMV

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.